The Engineered Lysin, CF-370, is Active Against Antibiotic-Resistant Gram-Negative Pathogens In vitro and Synergizes with Meropenem in Experimental Pseudomonas aeruginosa Pneumonia

By sjmartinez • February 18, 2024

Sauve K, Watson A, Oh JT, Swift S, Vila-Farres X, Abdelhady W, Xiong YQ, LeHoux D, Woodnutt G, Bayer AS, Schuch R. The Engineered Lysin, CF-370, is Active Against Antibiotic-Resistant Gram-Negative Pathogens In vitro and Synergizes with Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. J Infect Dis. 2024 Feb 15:jiae027. doi: 10.1093/infdis/jiae027. Epub ahead of print. PMID: 38366561.

Tags: ESKAPE pathogens, Harbor UCLA, Infectious Diseases, Lysin, multidrug-resistance, pneumonia, pseudomonas aeruginosa, Publications, synergy

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes[...]

Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism

Miner M, Wang C, Kaminetsky J, Khera M, Goldstein I, Carson C 3rd, Chidambaram N, King S, Dobs A. Safety, efficacy, and pharmacokinetics of oral[...]

Effect of Bimagrumab on body composition: a systematic review and meta-analysis

Kanbay M, Siriopol D, Copur S, Hasbal NB, Güldan M, Kalantar-Zadeh K, Garfias-Veitl T, von Haehling S. Effect of Bimagrumab on body composition: a systematic[...]